Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Uroplasty to similar companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This table compares Uroplasty and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Uroplasty and its peers top-line revenue, earnings per share (EPS) and valuation.
Uroplasty’s peers have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Uroplasty and its peers, as reported by MarketBeat.com.
||Strong Buy Ratings
As a group, “Medical Devices & Implants” companies have a potential upside of 37.35%. Given Uroplasty’s peers higher probable upside, analysts plainly believe Uroplasty has less favorable growth aspects than its peers.
Volatility & Risk
Uroplasty has a beta of -1.26, meaning that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s peers have a beta of 0.47, meaning that their average share price is 53% less volatile than the S&P 500.
Uroplasty peers beat Uroplasty on 6 of the 8 factors compared.
Uroplasty Company Profile
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.